Skip to main content

Table 3 Efficacy, coverage and adherence values used in base-case analysis

From: Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries

Intervention Efficacy Coverage Provider adherence Patient adherence
   Current Target Current Target Current Target
Drugs providing sustained headache relief       
ASA 1,000 mg 39% [21] 80% 90% 100% 100% 80% 90%
(Zambia 50%)
Sumatriptan 50 mg 35% [19] 2% (Zambia 80%) 75% 88% 56% 78%
(Zambia 1%)
Almotriptan 12.5 mg 45% [20] 0% 75% 88% 56% 78%
Drugs averting migraine attacks       
Propranolol 160 mg 28% [22] 3% 30% 75% 88% 71% 86%
Topiramate 100 mg 40% [23] 1% 75% 88% 60% 80%
Amitriptyline 100 mg 44% [24] 3% 75% 88% 42% 71%